In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zymeworks Inc.

www.zymeworks.com

Latest From Zymeworks Inc.

Finance Watch: Billions Of Dollars In Offerings Despite US Biopharma Stock Slump

Blueprint and Zymeworks raise $300m-plus in follow-on offerings. Also, Arcutis, Black Diamond and Annovis bring the 2020 US IPO count to four; Spring Bank, Surface Oncology and Decibel reveal strategic shifts; and Harmony’s $200m in venture debt leads recent VC deals.

Financing Innovation

AstraZeneca And Galapagos Shine At The 15th Annual Scrip Awards

The pharma, biotech and allied industries came together in London on 4 December to celebrate another year of achievement at the 15th Annual Scrip Awards, hosted by the broadcaster Fiona Bruce.

Commercial Companies

Finance Watch: Investors Bet On Hope As Four Early-Stage Companies Launch US IPOs

Public Company Edition: Of five drug developers expected to go public, four have preclinical or early clinical candidates, while the one that could not find a market for its IPO is in Phase III. Also, Biohaven, Zymeworks and Kura raise $100m or more in follow-on offerings.

Financing Business Strategies

Deal Watch: Parvus Signs Second Big Pharma Alliance, With Genentech

Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with Genentech. Iconic licenses ADC tech from Zymeworks, then out-licenses lead candidate to Exelixis.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Inflammation
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Zymeworks Inc.
  • Senior Management
  • Ali Tehrani, PhD, Pres. & CEO
    Neil Klompas, EVP, Bus. Operations & CFO
    Diana Hausman, MD, CMO
    David Poon, PhD, VP, Bus. Dev. & Alliance Mngmnt.
  • Contact Info
  • Zymeworks Inc.
    Phone: (604) 678-1388
    1385 West 8th Ave.
    Suite 540
    Vancouver, V6H 3V9
    Canada
UsernamePublicRestriction

Register